Gas money

Critical care company Ikaria Inc. is reportedly exploring a $2 billion buyout just three years after withdrawing an IPO that would have valued it at about $500 million. A takeout would be icing on the cake for investors already in the money based on dividends from revenues on the company's lone marketed product, INOmax inhaled nitric oxide.

Ikaria was formed in 2007 through the merger of Ikaria Inc. and INO Therapeutics. The predecessor Ikaria had a suite of preclinical hydrogen sulfide programs to treat transplantation and trauma indications, while INO marketed INOmax to treat hypoxic respiratory failure in term and near-term infants...